Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences' Trodelvy (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

11/24/2021 | 07:22am EST

FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan), a first-in-class Trop-2-directed antibody-drug conjugate, as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease.

'The metastatic stage of TNBC is particularly challenging to treat and until now we have urgently needed new treatment options for people in Europe living with this condition,' said Dr Veronique Dieras, Senior Medical Oncologist Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugene Marquis, Rennes, France. 'Today's approval including second-line metastatic TNBC is significant for the community as it's another important step forward in helping women with this disease live longer.'

TNBC is the most aggressive type of breast cancer and accounts for approximately 15% of all breast cancers. It is more frequently diagnosed in younger and premenopausal women and is more prevalent in Black and Hispanic women. The five-year survival rate for this sub-type of breast cancer is 12%, compared with 28% for other breast cancer types, and these poor outcomes are often coupled with a significant decrease in quality of life, especially in relapsed/refractory disease.

'At Gilead, we push boundaries to deliver transformative science and novel treatment options that address urgent medical needs,' said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. 'We understand how difficult metastatic TNBC is to treat and we're proud that Trodelvy can now offer a second-line treatment option with the potential to bring longer life to people living with this aggressive disease.'

The EC's decision is supported by results from the Phase 3 ASCENT study, where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician's choice of chemotherapy (HR: 0.51; 95% CI: 0.41-0.62; p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about GILEAD SCIENCES, INC.
01/19GLOBAL MARKETS LIVE : Bank of America, ASML, Intel, Oracle, Burberry...
01/19WALL STREET STOCK EXCHANGE : Temporary respite for the Nasdaq
01/19MARKETSCREENER’S WORLD PRESS REVIEW : January 19, 2022
01/19ANALYST RECOMMENDATIONS : Activision Blizzard, Chevron, Exxon Mobil, Gilead, Goldman Sachs..
01/19GILEAD SCIENCES : Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply..
PU
01/18Gilead says counterfeit HIV drugs ended up with patients
RE
01/18Health Care Down Amid Flight From Cyclical Sectors -- Health Care Roundup
DJ
01/18Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday..
BU
01/18Morgan Stanley Lowers Price Target for Gilead Sciences to $72 From $74, Maintains Equal..
MT
01/18Gilead says counterfeiting network sold $250 mln worth of its HIV drugs
RE
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 26 576 M - -
Net income 2021 7 176 M - -
Net Debt 2021 22 428 M - -
P/E ratio 2021 12,0x
Yield 2021 4,10%
Capitalization 86 640 M 86 640 M -
EV / Sales 2021 4,10x
EV / Sales 2022 4,26x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 69,07 $
Average target price 75,96 $
Spread / Average Target 9,97%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-4.88%86 640
REGENERON PHARMACEUTICALS-2.12%64 627
VERTEX PHARMACEUTICALS5.12%58 692
WUXI APPTEC CO., LTD.-6.39%51 406
BIONTECH SE-37.29%39 044
BEIGENE, LTD.-12.58%24 335